http://orcid.org/0000-0002-5842-7686
Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Dahai Hu, Xijiao Pang, Ji Luo, Jiaxin Zhou, Nan Wang, Hui Tang, Liang Wang & Xiaoxu Zhao. (2023) The correlation between the influencing factors and efficacy of immune checkpoint inhibitor therapy: an umbrella meta-analysis of randomized controlled trials. Annals of Medicine 55:1.
Read now
Read now
Jie Liu, Chengming Li, Samuel Seery, Jinming Yu & Xue Meng. (2020) Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis. OncoImmunology 9:1.
Read now
Read now
Zhen Wu, Zhen Yang, Yu Dai, Qiang Zhu & Liang-An Chen. (2019) Update on liquid biopsy in clinical management of non-small cell lung cancer. OncoTargets and Therapy 12, pages 5097-5109.
Read now
Read now
Articles from other publishers (38)
Qingyuan Huang, Hang Cao, Qianlan Yao, Xiaoyan Zhou, Hang Li, Qianming Bai & Hong Hu. (2023) NOTCH1 Mutations Predict Superior Outcomes of Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. ImmunoTargets and Therapy Volume 12, pages 165-173.
Crossref
Crossref
Xufen Zheng, Yuxiang Luo, Yangjie Xiong, Xiaoxiao Liu, Chunling Zeng, Xiaojing Lu, Xiaofang Wang, Yumei Cheng, Simin Wang, Haoqi Lan, Kai Wang, Zhonghui Weng, Wenbo Bi, Xinxin Gan, Xiaona Jia, Linhui Wang & Yuexiang Wang. (2023) Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway. Journal for ImmunoTherapy of Cancer 11:12, pages e007678.
Crossref
Crossref
Martina Catalano, Luigi Francesco Iannone, Gabriella Nesi, Stefania Nobili, Enrico Mini & Giandomenico Roviello. (2023) Immunotherapy-related biomarkers: Confirmations and uncertainties. Critical Reviews in Oncology/Hematology 192, pages 104135.
Crossref
Crossref
Milena Urbini, Sara Bleve, Giuseppe Schepisi, Cecilia Menna, Giorgia Gurioli, Caterina Gianni & Ugo De Giorgi. (2023) Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors. International Journal of Molecular Sciences 24:23, pages 16872.
Crossref
Crossref
Dafu Ye, Yao Jin, Yiming Weng, Xue Cui, Jinsong Wang, Min Peng & Qibin Song. (2023) High endothelial venules predict response to PD-1 inhibitors combined with anti-angiogenesis therapy in NSCLC. Scientific Reports 13:1.
Crossref
Crossref
Ke Ma, Qianqian Guo & Xingya Li. (2023) Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study. BMC Pulmonary Medicine 23:1.
Crossref
Crossref
Jiao Zhou, Shan Shi, Yeqing Qiu, Zhongwen Jin, Wenyan Yu, Rongzhi Xie & Hongyu Zhang. (2023) Integrative bioinformatics approaches to establish potential prognostic immune-related genes signature and drugs in the non-small cell lung cancer microenvironment. Frontiers in Pharmacology 14.
Crossref
Crossref
L.E. Hendriks, K.M. Kerr, J. Menis, T.S. Mok, U. Nestle, A. Passaro, S. Peters, D. Planchard, E.F. Smit, B.J. Solomon, G. Veronesi & M. Reck. (2023) Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology 34:4, pages 339-357.
Crossref
Crossref
Giuseppe Schepisi, Caterina Gianni, Maria Concetta Cursano, Valentina Gallà, Cecilia Menna, Chiara Casadei, Sara Bleve, Cristian Lolli, Giovanni Martinelli, Giovanni Rosti & Ugo De Giorgi. (2023) Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors. Frontiers in Immunology 14.
Crossref
Crossref
Natalie I. Vokes, Kelsey Pan & Xiuning Le. (2023) Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. Therapeutic Advances in Medical Oncology 15, pages 175883592311614.
Crossref
Crossref
Linlin Zhang, Shasha Guan, Fanlu Meng, Lin Teng & Diansheng Zhong. (2022) Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer. Frontiers in Oncology 12.
Crossref
Crossref
Kamya Sankar, Jing Christine Ye, Zihai Li, Lei Zheng, Wenru Song & Siwen Hu-Lieskovan. (2022) The role of biomarkers in personalized immunotherapy. Biomarker Research 10:1.
Crossref
Crossref
Thinh T. Nguyen, Hyun-Sung Lee, Bryan M. Burt, Jia Wu, Jianjun Zhang, Christopher I. Amos & Chao Cheng. (2022) A lepidic gene signature predicts patient prognosis and sensitivity to immunotherapy in lung adenocarcinoma. Genome Medicine 14:1.
Crossref
Crossref
S. Cox, C. Powell & S. Morgan. (2022) Implementing Genomic Testing for Lung Cancer Into Routine Clinical Practice – The Welsh Experience. Clinical Oncology 34:11, pages 716-723.
Crossref
Crossref
Mingyu Wang, Depeng Lu & Minghong Bi. (2022) Influence of concomitant gastric acid suppressants use on the survival of patients with non-small cell lung cancer treated with programmed death-1/ligand-1 inhibitors: A meta-analysis. International Immunopharmacology 110, pages 108955.
Crossref
Crossref
Lucy K. Corke, Janice J. N. Li, Natasha B. Leighl & Lawson Eng. (2022) Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer. Current Oncology 29:9, pages 6260-6276.
Crossref
Crossref
Natsuki Nakagawa & Masanori Kawakami. (2022) Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. Frontiers in Oncology 12.
Crossref
Crossref
Guanqun Yang, Ligang Xing & Xiaorong Sun. (2022) Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases. Frontiers in Immunology 13.
Crossref
Crossref
Krishna Patel, Naomi Alpert, Stephanie Tuminello & Emanuela Taioli. (2022) Association of Personal Characteristics and Effectiveness of Immunotherapy in Late-Stage Non-Small Cell Lung Cancer: A Systematic Review. JNCI Cancer Spectrum 6:2.
Crossref
Crossref
Hirva Mamdani, Sandro Matosevic, Ahmed Bilal Khalid, Gregory Durm & Shadia I. Jalal. (2022) Immunotherapy in Lung Cancer: Current Landscape and Future Directions. Frontiers in Immunology 13.
Crossref
Crossref
Rui An, Feng Zhao, Liqian Wang, Jikang Shan & Xianjun Wang. (2021) Predictive effect of molecular and clinical characteristics for the OS and PFS efficacy of anti-PD-1/PD-L1 immunotherapy in patients with NSCLC: a meta-analysis and systematic review. BMJ Open 11:12, pages e047663.
Crossref
Crossref
Jie Zhang, Zhujiang Dai, Cheng Yan, Wenjie Zhang, Daorong Wang & Dong Tang. (2021) A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics. Clinical and Translational Oncology 23:12, pages 2415-2430.
Crossref
Crossref
Sukhmani K. Padda, Jacqueline V. Aredo, Shireen Vali, Neeraj K. Singh, Sumanth M. Vasista, Ansu Kumar, Joel W. Neal, Taher Abbasi & Heather A. Wakelee. (2021)
Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of
KRAS
-Mutated Non–Small-Cell Lung Cancer
. JCO Precision Oncology:5, pages 153-162.
Crossref
Crossref
Guo-Hua Huang, Yu-Hang Zhang, Lei Chen, You Li, Tao Huang & Yu-Dong Cai. (2021) Identifying Lung Cancer Cell Markers with Machine Learning Methods and Single-Cell RNA-Seq Data. Life 11:9, pages 940.
Crossref
Crossref
Apostolia-Maria Tsimberidou, Henry Hiep Vo, Vivek Subbiah, Filip Janku, Sarina Piha-Paul, Bulent Yilmaz, Jing Gong, Mohammad Faraz Naqvi, Shi-Ming Tu, Matthew Campbell, Funda Meric-Bernstam & Aung Naing. (2021) Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. The Oncologist 26:7, pages 558-e1098.
Crossref
Crossref
Rachel E. Gemine, Syedah Aleena Haider, Sofia Belo Ravara & Keir E. Lewis. 2021. Supporting Tobacco Cessation. Supporting Tobacco Cessation
165
180
.
Ryota Shibaki, Hiroaki Akamatsu, Terufumi Kato, Kazumi Nishino, Morihito Okada, Tetsuya Mitsudomi, Kazushige Wakuda, Kenichi Yoshimura, Nobuyuki Yamamoto & Kazuhiko Nakagawa. (2021)
A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with
EGFR
mutation (West Japan Oncology Group 11719L/ADJUST study)
. Therapeutic Advances in Medical Oncology 13, pages 175883592098764.
Crossref
Crossref
Diego L. Kaen, Nicolas Minatta, Alessandro Russo, Umberto Malapelle, Diego de Miguel-Pérez & Christian Rolfo. 2021. Immunotherapy. Immunotherapy
113
142
.
Fangfang Liu, Xun Yuan, Jizong Jiang & Qian Chu. (2020)
Immunotherapy in advanced non-small-cell lung cancer with
EGFR
mutations
. Immunotherapy 12:16, pages 1195-1207.
Crossref
Crossref
Alexander F.C. Hulsbergen, Marco Mammi, Steven H.J. Nagtegaal, Asad M. Lak, Vasileios Kavouridis, Timothy R. Smith, Julian B. Iorgulescu, Rania A. Mekary, Joost J.C. Verhoeff, Marike L.D. Broekman & John G. Phillips. (2020) Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy. International Journal of Radiation Oncology*Biology*Physics 108:1, pages 258-267.
Crossref
Crossref
Josephine Hai, Hua Zhang, Jin Zhou, Zhong Wu, Ting Chen, Eleni Papadopoulos, Catríona M. Dowling, Val Pyon, Yuanwang Pan, Jie Bin Liu, Roderick T. Bronson, Heather Silver, Patrick H. Lizotte, Jiehui Deng, Joshua D. Campbell, Lynette M. Sholl, Christine Ng, Ming-Sound Tsao, Cassandra Thakurdin, Adam J. Bass & Kwok-Kin Wong. (2020) Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy. Clinical Cancer Research 26:13, pages 3431-3442.
Crossref
Crossref
Antonio Calles, Jonathan W. Riess & Julie R. Brahmer. (2020) Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely. American Society of Clinical Oncology Educational Book:40, pages 372-384.
Crossref
Crossref
Chengming Liu, Sufei Zheng, Runsen Jin, Xinfeng Wang, Feng Wang, Ruochuan Zang, Haiyan Xu, Zhiliang Lu, Jianbing Huang, Yuanyuan Lei, Shuangshuang Mao, Yalong Wang, Xiaoli Feng, Nan Sun, Yan Wang & Jie He. (2020) The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Letters 470, pages 95-105.
Crossref
Crossref
Babak Baseri, Bachar Samra, Eric Tam, Edwin Chiu & Andrea Leaf. (2019) An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors. Case Reports in Oncological Medicine 2019, pages 1-7.
Crossref
Crossref
Rui-Lian Chen, Jing-Xu Zhou, Yang Cao, Sui-Hui Li, Yong-Hao Li, Mei Jiang, Dong-Yan Lu, Peng Li & Li-Zhu Lin. (2019) The efficacy of PD-1/PD-L1 inhibitors in advanced squamous-cell lung cancer: a meta-analysis of 3112 patients. Immunotherapy 11:17, pages 1481-1490.
Crossref
Crossref
Kun Huang, Erqiang Hu, Wan Li, Junjie Lv, Yuehan He, Gui Deng, Jinling Xiao, Chengcheng Yang, Xinyu Zhao, Lina Chen & Xinyan Wang. (2019) Association of PD-1 polymorphisms with the risk and prognosis of lung adenocarcinoma in the northeastern Chinese Han population. BMC Medical Genetics 20:1.
Crossref
Crossref
Sohita Dhillon & Yahiya Y. Syed. (2019) Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC. Targeted Oncology 14:6, pages 759-768.
Crossref
Crossref
Rundo, Spampinato, Banna & Conoci. (2019) Advanced Deep Learning Embedded Motion Radiomics Pipeline for Predicting Anti-PD-1/PD-L1 Immunotherapy Response in the Treatment of Bladder Cancer: Preliminary Results. Electronics 8:10, pages 1134.
Crossref
Crossref